Eluvixtamab

{
  "id": "MLC-T-ONC-013316",
  "term": "Eluvixtamab",
  "field": "Oncology and biomedicine",
  "definition": "A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of eluvixtamab, this bispecific antibody binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on neoplastic cells in patients with acute myeloid leukemia.",
  "synonyms": [
    "anti-CD33/CD3 BiTE antibody AMG 330",
    "CD33/CD3-directed bispecific T-cell engager antibody AMG 330",
    "BiTE antibody AMG 330",
    "bispecific T-cell engager antibody AMG 330"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/eluvixtamab/"
}